AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16034518 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebeccamycin analogue (RA) 140 mg/m(2)/day x 5 days repeated every 3 weeks (Arm B)
Number of subjects: 42
Study 12477578 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 55
Study 12477578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 10539878 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative transfusion regimen (conservative to bring hemoglobin concentration to between 9 and 11 g/dl)
Number of subjects: 118
Study 10539878 — intervention group
Group type: COMPARATOR
Intervention: Preoperative transfusion regimen (aggressive to lower hemoglobin S level to 30%)
Number of subjects: 118
Study 10539878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip replacements
Number of subjects: 118
Study 10539878 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip coring procedures
Number of subjects: 118
Study 10539878 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perioperative care guidelines compliance
Number of subjects: 118
Study 10539878 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion complications
Number of subjects: 118
Study 10539878 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical complications after hip replacements
Number of subjects: 118
Study 10539878 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaths following surgery
Number of subjects: 118
Study 8955454 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nalidixic acid and metronidazole
Number of subjects: 156
Study 8955454 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole alone
Number of subjects: 156
Study 8955454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 2011075 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein diet (23% of energy as protein)
Number of subjects: 10
Study 7134028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide 120 ng/kg b. wt/hr
Number of subjects: 24
Study 7134028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceruletide 60 ng/kg b. wt/hr
Number of subjects: 24
Study 7134028 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 24
Study 31991898 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega-3 and omega-6 fatty acids supplementation with antioxidant vitamins (20 mL containing 810 mg Eicosapentaenoic acid, 4140 mg Docosahexaenoic acid, 1800 mg gamma-Linolenic acid, 3150 mg Linoleic acid, 0.6 mg vitamin A, 22 mg vitamin E, 760 mg pure γ-tocopherol)
Number of subjects: 46
Study 30397906 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hyperventilation (ICHV)
Number of subjects: 25
Study 30397906 — intervention group
Group type: COMPARATOR
Intervention: Normoventilation
Number of subjects: 25
Study 28986051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 0.2 mg/kg dexamethasone (group D)
Number of subjects: 80
Study 28986051 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group P)
Number of subjects: 80
Study 25896330 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPA filtration
Number of subjects: 83
Study 25896330 — intervention group
Group type: COMPARATOR
Intervention: Placebo filtration
Number of subjects: 83
Study 25896330 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor PM2.5 exposure in traffic-impacted locations
Number of subjects: 83
Study 25896330 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor PM2.5 exposure in woodsmoke-impacted locations
Number of subjects: 83
Study 25060792 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich olive oil (366 mg/kg)
Number of subjects: 47
Study 25060792 — intervention group
Group type: COMPARATOR
Intervention: Polyphenol-poor olive oil (2.7 mg/kg)
Number of subjects: 47
Study 22000326 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session adolescent-only intervention (BI-A)
Number of subjects: 315
Study 22000326 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session adolescent and additional parent session (BI-AP)
Number of subjects: 315
Study 22000326 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition (CON)
Number of subjects: 315
Study 19415056 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine Clonixinate
Number of subjects: 64
Study 19415056 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 64
Study 19415056 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyrone
Number of subjects: 64
Study 19415056 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 17717452 — intervention group
Group type: EXPERIMENTAL
Intervention: Coloplasty (CP-1)
Number of subjects: 364
Study 17717452 — intervention group
Group type: COMPARATOR
Intervention: Straight Anastomosis (SA)
Number of subjects: 364
Study 17717452 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-Pouch (JP)
Number of subjects: 364
Study 17717452 — intervention group
Group type: COMPARATOR
Intervention: Coloplasty (CP-2)
Number of subjects: 364
Study 17717452 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) scores
Number of subjects: 364
Study 14768624 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP light (400-3400 nm, 95% polarization, 40 mW cm(‐2), 12 J cm(‐2))
Number of subjects: 0
Study 14768624 — intervention group
Group type: EXPERIMENTAL
Intervention: VInP light (400-3400 nm, no polarization, 38 mW cm(‐2), 11.2 J cm(‐2))
Number of subjects: 0
Study 11270012 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl administered 15 min before surgery (group I)
Number of subjects: 40
Study 11270012 — intervention group
Group type: COMPARATOR
Intervention: Epidural fentanyl administered 15 min before waking at the end of the operation (group II)
Number of subjects: 40
Study 9509205 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5 mg.kg‐1
Number of subjects: 52
Study 9509205 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 1.0 mg.kg‐1
Number of subjects: 52
Study 7830998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreon as an intraoperative hydrokinetic retinal manipulator
Number of subjects: 234
Study 7830998 — intervention group
Group type: COMPARATOR
Intervention: C3F8, SF6, silicone oil as postoperative tamponading agents
Number of subjects: 234
Study 7830998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitreon as a short-term tamponade
Number of subjects: 234
Study 2905250 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate 150 mg daily at 9 pm for 14 days
Number of subjects: 0
Study 2905250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30121609 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple pill (fixed low-dose combination of three antihypertensive drugs)
Number of subjects: 0
Study 30121609 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 26801948 — intervention group
Group type: EXPERIMENTAL
Intervention: 3:1 C:V method
Number of subjects: 84
Study 26801948 — intervention group
Group type: EXPERIMENTAL
Intervention: 9:3 C:V method
Number of subjects: 84
Study 26801948 — intervention group
Group type: EXPERIMENTAL
Intervention: 15:2 C:V method
Number of subjects: 84
Study 26801948 — intervention group
Group type: COMPARATOR
Intervention: CCaV-120 method
Number of subjects: 84
Study 26253237 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported self-management intervention
Number of subjects: 80
Study 26253237 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 80
Study 26253237 — intervention group
Group type: COMPARATOR
Intervention: Both arms (supported self-management and standard treatment)
Number of subjects: 80
Study 24240932 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight management
Number of subjects: 150
Study 24240932 — intervention group
Group type: COMPARATOR
Intervention: General lifestyle advice (Control)
Number of subjects: 150
Study 21174051 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BOTOX®, Allergan Inc.) + standard care
Number of subjects: 300
Study 21174051 — intervention group
Group type: COMPARATOR
Intervention: Placebo + standard care
Number of subjects: 300
Study 18281242 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-ovulatory pertubation with low-dose lignocaine
Number of subjects: 130
Study 18281242 — intervention group
Group type: COMPARATOR
Intervention: No pertubation
Number of subjects: 130
Study 16532491 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein (GP) IIb/IIIa inhibitors
Number of subjects: 81
Study 12649057 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral smoking cessation treatment plus moderate-intensity physical activity
Number of subjects: 217
Study 12649057 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral smoking cessation treatment plus contact control
Number of subjects: 217
Study 11573317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sting-Aid (aluminum sulfate solution)
Number of subjects: 0
Study 11573317 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolph's meat tenderizer dissolved in water
Number of subjects: 0
Study 11573317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh water
Number of subjects: 0
Study 11573317 — intervention group
Group type: COMPARATOR
Intervention: Control (seawater)
Number of subjects: 0
Study 9692778 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 (15 microg min(‐1) for 60 min and subsequently 60 microg min(‐1) for 60 min)
Number of subjects: 10
Study 9692778 — intervention group
Group type: EXPERIMENTAL
Intervention: ET‐1 (2.5 ng kg(‐1) min(‐1) for 120 min)
Number of subjects: 10
Study 9692778 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ‐123 co-infused with ET-1
Number of subjects: 10
Study 8139627 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta (250 IU/kg subcutaneously three times a week from day 3 to day 42)
Number of subjects: 241
Study 8139627 — intervention group
Group type: COMPARATOR
Intervention: Control (no epoetin treatment)
Number of subjects: 241
Study 8139627 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Number of subjects: 241
Study 8139627 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 241
Study 3340660 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal stabilization procedure
Number of subjects: 15
Study 3340660 — intervention group
Group type: COMPARATOR
Intervention: Minimal stabilization procedure
Number of subjects: 15
Study 31539628 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 22
Study 31539628 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine
Number of subjects: 22
Study 31539628 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 22
Study 31539628 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 22
Study 31539628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30807755 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched limb training
Number of subjects: 20
Study 30807755 — intervention group
Group type: COMPARATOR
Intervention: Mismatched limb training
Number of subjects: 20
Study 28922340 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous non-invasive BP monitoring
Number of subjects: 160
Study 28922340 — intervention group
Group type: COMPARATOR
Intervention: Control group (intermittent BP monitoring only)
Number of subjects: 160
Study 26169781 — intervention group
Group type: COMPARATOR
Intervention: Prenatal oral vitamin D3 supplementation (4200 IU/wk)
Number of subjects: 1300
Study 26169781 — intervention group
Group type: COMPARATOR
Intervention: Prenatal oral vitamin D3 supplementation (16,800 IU/wk)
Number of subjects: 1300
Study 26169781 — intervention group
Group type: COMPARATOR
Intervention: Prenatal oral vitamin D3 supplementation (28,000 IU/wk)
Number of subjects: 1300
Study 26169781 — intervention group
Group type: COMPARATOR
Intervention: Postpartum oral vitamin D3 supplementation (28,000 IU/wk)
Number of subjects: 1300
Study 26169781 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in the prenatal period
Number of subjects: 1300
Study 26169781 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo in the postpartum period
Number of subjects: 1300
Study 23454404 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg desmopressin orally disintegrating tablet once daily
Number of subjects: 261
Study 23454404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 21570355 — intervention group
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV‐1 vaccine
Number of subjects: 801
Study 21570355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 801
Study 20016978 — intervention group
Group type: EXPERIMENTAL
Intervention: Figures with 'holes'
Number of subjects: 0
Study 20016978 — intervention group
Group type: EXPERIMENTAL
Intervention: Figures with 'no-holes'
Number of subjects: 0
Study 16339157 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin at SDC 0.5-0.9 ng/mL
Number of subjects: 5548
Study 16339157 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin at SDC >=1.0 ng/mL
Number of subjects: 5548
Study 16339157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5548
Study 15322438 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 11132321 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH) administered subcutaneously at a dose of 0.5 lU/kg per day for 28 days
Number of subjects: 49
Study 11132321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 11132321 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant growth hormone (rGH)
Number of subjects: 49
Study 9358208 — intervention group
Group type: EXPERIMENTAL
Intervention: Myogard (test product)
Number of subjects: 22
Study 8118901 — intervention group
Group type: EXPERIMENTAL
Intervention: Active motion and continuous passive motion (CPM) rehabilitation
Number of subjects: 0
Study 8118901 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical therapy
Number of subjects: 0
Study 30659990 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff Vision
Number of subjects: 200
Study 30659990 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 200
Study 29617704 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive false feedback (active neurofeedback expectation)
Number of subjects: 46
Study 29617704 — intervention group
Group type: COMPARATOR
Intervention: Negative false feedback (placebo with false feedback)
Number of subjects: 46
Study 28134676 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position
Number of subjects: 82
Study 28134676 — intervention group
Group type: COMPARATOR
Intervention: Traction table
Number of subjects: 82
Study 26325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 7.5 mg/d
Number of subjects: 821
Study 26325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 10 mg/d
Number of subjects: 821
Study 26325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 15 mg/d
Number of subjects: 821
Study 26325557 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone 20 mg/d
Number of subjects: 821
Study 26325557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 821
Study 26325557 — intervention group
Group type: COMPARATOR
Intervention: Finerenone and Placebo
Number of subjects: 821
Study 22484413 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20mg, t.i.d.) for 6 months
Number of subjects: 40
Study 22484413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21527115 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin + pioglitazone
Number of subjects: 46
Study 21527115 — intervention group
Group type: COMPARATOR
Intervention: Metformin + glimepiride
Number of subjects: 46
Study 18958842 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone (8 mg daily)
Number of subjects: 12
Study 18958842 — intervention group
Group type: COMPARATOR
Intervention: glimepiride (3 mg daily)
Number of subjects: 12
Study 16760682 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12663295 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-supplemented cereal (0.55 g/15 g cereal)
Number of subjects: 631
Study 12663295 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented cereal
Number of subjects: 631
Study 12663295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal fortified with zinc (1 mg/15 g cereal)
Number of subjects: 631
Study 12663295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal containing both zinc and prebiotics
Number of subjects: 631
Study 11214033 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 6
Study 11214033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 8633815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine, zidovudine, and didanosine (triple-combination regimen)
Number of subjects: 398
Study 8633815 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine and didanosine (double-combination regimen)
Number of subjects: 398
Study 1814737 — intervention group
Group type: EXPERIMENTAL
Intervention: dipyridamole-beta-cyclodextrin complex (dip-beta-CD)
Number of subjects: 12
Study 1814737 — intervention group
Group type: COMPARATOR
Intervention: dipyridamole
Number of subjects: 12
Study 6668457 — intervention group
Group type: EXPERIMENTAL
Intervention: Heme-iron supplementation
Number of subjects: 0
Study 6668457 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31930222 — intervention group
Group type: EXPERIMENTAL
Intervention: DIVER‐100® (2 capsules/day for 10 days per month, for 3 months)
Number of subjects: 101
Study 31930222 — intervention group
Group type: EXPERIMENTAL
Intervention: DIVER‐100®
Number of subjects: 101
Study 29554535 — intervention group
Group type: EXPERIMENTAL
Intervention: escitalopram (10 mg twice/day) + CBX (200 mg twice/day)
Number of subjects: 47
Study 29554535 — intervention group
Group type: COMPARATOR
Intervention: escitalopram (10 mg twice/day) + placebo (twice/day)
Number of subjects: 47
Study 29554535 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (N = 35)
Number of subjects: 47
Study 26727475 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP system plus heated humidifier and an integrated heated breathing tube
Number of subjects: 88
Study 26727475 — intervention group
Group type: COMPARATOR
Intervention: CPAP system plus conventional heated humidifier
Number of subjects: 88
Study 24560438 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine 40 mg
Number of subjects: 82
Study 24560438 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 22234683 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 100 mg twice daily
Number of subjects: 41
Study 22234683 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 200 mg once daily
Number of subjects: 41
Study 22234683 — intervention group
Group type: COMPARATOR
Intervention: Plain aspirin 100 mg once daily
Number of subjects: 41
Study 19781072 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus (RV) group
Number of subjects: 50
Study 19781072 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RV and RSV groups
Number of subjects: 50
Study 17471113 — intervention group
Group type: EXPERIMENTAL
Intervention: HSV-2 serologic testing
Number of subjects: 344
Study 17471113 — intervention group
Group type: COMPARATOR
Intervention: HSV-2 negative or previously diagnosed participants
Number of subjects: 344
Study 15209959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 30 mg b.i.d.
Number of subjects: 0
Study 15209959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15209959 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine (any dose)
Number of subjects: 0
Study 15209959 — intervention group
Group type: EXPERIMENTAL
Intervention: Any fexofenadine doses
Number of subjects: 0
Study 11260249 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin cream (5%) applied 4 times daily for 3 days
Number of subjects: 11
Study 11260249 — intervention group
Group type: COMPARATOR
Intervention: Basic ointment (control) applied 4 times daily for 3 days
Number of subjects: 11
Study 10176088 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity home-based exercise
Number of subjects: 63
Study 10176088 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity class-based exercise
Number of subjects: 63
Study 10176088 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity home-based exercise
Number of subjects: 63
Study 10176088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence change during the adoption phase
Number of subjects: 63
Study 10176088 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline self-efficacy
Number of subjects: 63
Study 8047334 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray application of 1% cyclopentolate hydrochloride
Number of subjects: 37
Study 8047334 — intervention group
Group type: COMPARATOR
Intervention: Drop instillation of 1% cyclopentolate hydrochloride
Number of subjects: 37
Study 8047334 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray application of cyclopentolate hydrochloride
Number of subjects: 37
Study 8047334 — intervention group
Group type: COMPARATOR
Intervention: Drop instillation of cyclopentolate hydrochloride
Number of subjects: 37
Study 8047334 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 37
Study 2557203 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive-oil-rich diet
Number of subjects: 124
Study 2557203 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate-rich, high-fibre diet
Number of subjects: 124
Study 31375390 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS wedge resection
Number of subjects: 424
Study 31375390 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS segmentectomy
Number of subjects: 424
Study 31375390 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS lobectomy
Number of subjects: 424
Study 31375390 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 424
Study 30888330 — intervention group
Group type: EXPERIMENTAL
Intervention: tablet+messages
Number of subjects: 1500